The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Photo by Md. Tareq Aziz Touhid.

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. There has been a flurry of other licensing and M&A deals in the RNA space since the start of the pandemic, headlined by Sanofi’s $3.2

RNA 52

RNA Immune Response Vaccination Vaccine 52

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

STAT News

NOVEMBER 24, 2022

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Pharmaceutical Technology

AUGUST 1, 2022

They intend to develop vaccines that provide lasting immune responses compared to existing vaccines. In March, the company entered a licensing agreement with Serum Institute of India (SII) to expedite access to messenger RNA products in emerging markets worldwide.

Vaccination 245

Vaccination Vaccine Development RNA 245

Drug Discovery World

FEBRUARY 19, 2024

At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Pharmaceutical Technology

OCTOBER 14, 2022

In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs. The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Scienmag

MARCH 17, 2021

How one long noncoding RNA could help improve outcomes in bone marrow and solid organ transplantation A long noncoding RNA whose function was previously unknown turns out to play a vital role in mobilizing the immune response following a bone marrow transplant or solid organ transplantation.

RNA 61

RNA Immune Response Medicine 61

Pharmaceutical Technology

JUNE 30, 2022

The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. This technology can stimulate an immune response with a dose up to 20 times lower than current vaccines, which enhances safety, lowers costs, and increases production speed. .

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Drug Discovery World

NOVEMBER 17, 2022

The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease. . As part of the study, RNA sequencing was conducted using blood samples from 152 patients with symptoms of post-treatment Lyme disease to measure their immune response. .

Genetics 52

Genetics RNA Immune Response Bioinformatics 52

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Delveinsight

SEPTEMBER 23, 2021

858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. 858’s drug candidates include proteins, which regulate RNA and immune response.

RNA 61

RNA Gene Therapy Gene Protein 61

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying biology – eg. In terms of technical process, traditional RNA sequencing was a very laborious process that could take several weeks and was prone to errors. SB: Certainly.

RNA 52

RNA Drugs Gene Expression Gene 52

Drug Discovery World

NOVEMBER 30, 2022

Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response. .

Production 52

Production Immune Response RNA Gene 52

Drug Discovery World

JANUARY 12, 2024

Study reveals therapeutic potential of mRNA in rare diseases Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people.

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Pharmaceutical Technology

JUNE 8, 2023

The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

Camargo

JULY 27, 2021

As with any standard drug treatment, gene therapies carry potential risks, including adverse events, unexpected gene modification (activation or inactivation), undesired immune responses, or complications with the genetic material. Route of Administration Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

SEPTEMBER 14, 2021

Rome Therapeutics – which officially launched last year – has made shining a light on the so-called ‘dark genome’ its mission, and has already discovered that repeats can play a critical role in human health, such as by switching on the innate immune response under stress.

DNA 52

DNA Immune Response Genome Genomics 52

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 124

Protein Vaccination Vaccine Immune Response 124

Pharmaceutical Technology

FEBRUARY 15, 2023

The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

The Pharma Data

MARCH 8, 2022

Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA. Camouflage protects virus from immune system. For example, viral RNAs are masked by the addition of a methyl group. “A robust, early type I IFN production is key to clearing SARS-CoV-2 infection.

Immune Response 52

Immune Response RNA Protein Genetics 52

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. In a study where the antiviral activity of Sunlenca was evaluated in combination with an optimized background regimen, 87.5 percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

OCTOBER 2, 2020

NEO, which is designed to be produced on-demand according to the neoantigen profile of an individual patient and produces an immune response that attacks the tumour. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology. The deal focuses on Vaccibody’s investigational product VB10.NEO,

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

Drug Discovery World

MAY 18, 2023

This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccination 40

Vaccination Vaccine Immune Response RNA 40

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccination 52

Vaccination Vaccine Immune Response Gene Expression 52

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Drug Discovery World

JULY 26, 2022

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The lecture will be delivered in two halves by U?ur ahin and Özlem Türeci, co-founders of BioNtech. .

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. The major difference between siRNAs and microRNAs is that the former are very specific to one messenger RNA target, while the latter can have multiple targets.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

pharmaphorum

OCTOBER 6, 2020

The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Immune Response 52

Immune Response Vaccination Vaccine FDA Approval 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

NOVEMBER 2, 2022

The promise in the self-assembling RNA technology lies in its potential to achieve a strong immune response using a lower dose of antigen than the current generation of mRNA shots, although it is generally a larger molecule and may be more challenging to deliver.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52